skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Psychopharmacology of ADHD in pediatrics: current advances and issues

Review

(4195) Views  (1292) Full article downloads

Authors: Donald E Greydanus, Ahsan Nazeer, Dilip R Patel

Published Date March 2009 Volume 2009:5 Pages 171 - 181
DOI: http://dx.doi.org/10.2147/NDT.S4075

Donald E Greydanus, Ahsan Nazeer, Dilip R Patel

Michigan State University College of Human Medicine, Michigan State University/Kalamazoo Center for Medical Studies, Kalamazoo, MI, USA

Abstract: Attention deficit hyperactivity disorder (ADHD) is a neurobehavioral developmental disorder found in 3% to 8% of children and adolescents. An important part of ADHD management is psychopharmacology, which includes stimulants, norepinephrine reuptake inhibitors, alpha-2 agonists, and antidepressants. Medications with the best evidence-based support for ADHD management are the stimulants methylphenidate and amphetamine. A number of newer, long-acting stimulants are now available and a number of new medications are considered that are under current research.

Keywords: ADHD, methylphenidate, amphetamine, norepinephrine reuptake inhibitors, alpha-2 agonists, antidepressants






 

Other articles by Professor Donald Greydanus



Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Management of attention-deficit hyperactivity disorder in adults: focus on methylphenidate hydrochloride
Erratum
Solid self-nanoemulsifying cyclosporin A pellets prepared by fluid-bed coating: preparation, characterization and in vitro redispersibility
Editorial
Improvement of adenoviral vector-mediated gene transfer to airway epithelia by folate-modified anionic liposomes
Perception of risk and benefit in patient-centered communication and care
The relationship between deliberate self-harm behavior, body dissatisfaction, and suicide in adolescents: current concepts
Zinc oxide nanoparticles as selective killers of proliferating cells
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy